The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

被引:27
作者
Schmitz, Susanne [1 ]
Maguire, Aine [2 ,3 ]
Morris, James [4 ]
Ruggeri, Kai [3 ,14 ]
Haller, Elisa [5 ]
Kuhn, Isla [6 ]
Leahy, Joy [7 ]
Homer, Natalia [4 ]
Khan, Ayesha [8 ]
Bowden, Jack [9 ]
Buchanan, Vanessa [4 ]
O'Dwyer, Michael [10 ]
Cook, Gordon [11 ,12 ]
Walsh, Cathal [13 ]
机构
[1] Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, Luxembourg
[2] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland
[3] Univ Cambridge, Dept Psychol, Cambridge, England
[4] Cogentia Healthcare Consulting, Cambridge, England
[5] Univ Zurich, Dept Psychol, Zurich, Switzerland
[6] Univ Cambridge, Univ Lib Med Lib, Cambridge, England
[7] Trinity Coll Dublin, Dept Comp Sci & Stat, Dublin, Ireland
[8] Univ Exeter, Exeter, Devon, England
[9] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England
[10] NUI Galway, Dept Med, Galway, Ireland
[11] St James Univ Hosp, Haematol & Myeloma Studies, Leeds, W Yorkshire, England
[12] St James Univ Hosp, NIHR MIC DEL, Leeds, W Yorkshire, England
[13] Univ Limerick, Hlth Res Inst, Limerick, Ireland
[14] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2018年 / 18卷
关键词
Network meta-analysis; Single armed studies; Evidence synthesis; Relapsed or refractory myeloma; LENALIDOMIDE PLUS DEXAMETHASONE; ADJUSTED INDIRECT COMPARISONS; MIXED TREATMENT COMPARISONS; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; PROPENSITY SCORE; REFRACTORY MYELOMA; TREATMENT OUTCOMES; BORTEZOMIB; THERAPY;
D O I
10.1186/s12874-018-0509-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Network meta-analysis (NMA) allows for the estimation of comparative effectiveness of treatments that have not been studied in head-to-head trials; however, relative treatment effects for all interventions can only be derived where available evidence forms a connected network. Head-to-head evidence is limited in many disease areas, regularly resulting in disconnected evidence structures where a large number of treatments are available. This is also the case in the evidence of treatments for relapsed or refractory multiple myeloma. Methods: Randomised controlled trials (RCTs) identified in a systematic literature review form two disconnected evidence networks. Standard Bayesian NMA models are fitted to obtain estimates of relative effects within each network. Observational evidence was identified to fill the evidence gap. Single armed trials are matched to act as each other's control group based on a distance metric derived from covariate information. Uncertainty resulting from including this evidence is incorporated by analysing the space of possible matches. Results: Twenty five randomised controlled trials form two disconnected evidence networks; 12 single armed observational studies are considered for bridging between the networks. Five matches are selected to bridge between the networks. While significant variation in the ranking is observed, daratumumab in combination with dexamethasone and either lenalidomide or bortezomib, as well as triple therapy of carfilzomib, ixazomib and elozumatab, in combination with lenalidomide and dexamethasone, show the highest effects on progression free survival, on average. Conclusions: The analysis shows how observational data can be used to fill gaps in the existing networks of RCT evidence; allowing for the indirect comparison of a large number of treatments, which could not be compared otherwise. Additional uncertainty is accounted for by scenario analyses reducing the risk of over confidence in interpretation of results.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
    Dolph, Michael
    Tremblay, Gabriel
    Gilligan, Adrienne M.
    Leong, Hoyee
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2021, 8 (02): : 26 - 35
  • [22] A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
    Dimopoulos, Meletios Athanasios
    Kaufman, Jonathan L.
    White, Darrell
    Cook, Gordon
    Rizzo, Maria
    Xu, Yingxin
    Fahrbach, Kyle
    Gaudig, Maren
    Slavcev, Mary
    Dearden, Lindsay
    Lam, Annette
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (03) : 163 - +
  • [23] Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
    Botta, Cirino
    Martino, Enrica Antonia
    Conticello, Concetta
    Mendicino, Francesco
    Vigna, Ernesto
    Romano, Alessandra
    Palumbo, Giuseppe Antonio
    Cerchione, Claudio
    Martinelli, Giovanni
    Morabito, Fortunato
    Di Raimondo, Francesco
    Gentile, Massimo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple Myeloma: a Meta-analysis of Data from Clinical Trials
    Chen, Runzhe
    Chen, Baoan
    Zhang, Xiaoping
    Gao, Chong
    DISCOVERY MEDICINE, 2016, 22 (121) : 189 - 199
  • [25] Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    DerSarkissian, Maral
    Cranmer, Holly
    Dabora, Jonathan
    Bocharova, Iryna
    Cherepanov, Dasha
    Cheng, Mu
    Bhak, Rachel H.
    Duh, Mei Sheng
    HEMATOLOGY, 2023, 28 (01)
  • [26] Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
    Van Beurden-Tan, Chrissy H. Y.
    Sonneveld, Pieter
    Uyl-de Groot, Carin A.
    BMC CANCER, 2022, 22 (01)
  • [27] Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis
    Xu, Wenjun
    Li, DianFang
    Sun, Yanhua
    Ran, Xuehong
    Wang, Baohong
    Wu, Wei
    Sheng, Zhixin
    Liu, Liping
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (06) : 542 - 551
  • [28] Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials
    Singh, Janharpreet
    Gsteiger, Sandro
    Wheaton, Lorna
    Riley, Richard D.
    Abrams, Keith R.
    Gillies, Clare L.
    Bujkiewicz, Sylwia
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [29] A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
    Weisela, Katja
    Doyen, Chantal
    Dimopoulos, Meletios
    Yee, Adrian
    Jose Lahuerta, Juan
    Martin, Amber
    Travers, Karin
    Druyts, Eric
    Toor, Kabirraaj
    Abildgaard, Niels
    Lu, Jin
    Van Droogenbroeck, Jan
    Geraldes, Catarina
    Petrini, Mario
    Voillat, Laurent
    Voog, Eric
    Facon, Thierry
    LEUKEMIA & LYMPHOMA, 2017, 58 (01) : 153 - 161
  • [30] A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma
    Mohyuddin, Ghulam Rehman
    Hampton, Jill
    Aziz, Muhammad
    Khuder, Sadik
    Malik, Saad
    McClune, Brian
    Abdallah, Al-Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07) : 489 - 496